A multimodality work‐up of patients with Hypereosinophilia
- 26 September 2018
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 93 (11) , 1337-1346
Abstract
The work‐up of patients with hypereosinophilia (HE) is complex. Following the recently revised World Health Organization criteria, we retrospectively reviewed 125 patients who were referred to us to exclude a neoplastic cause of HE (2003‐2016). The clinical laboratory work‐up confirmed secondary HE in 25 (20%) patients; myeloid/lymphoid neoplasms with rearrangements of PDGFRA (n = 9) or PDGFRB (n = 2) (9%); HE associated with a well‐defined myeloid neoplasm in 8 (6%); and abnormal bone marrow and/or molecular genetic abnormalities consistent with chronic eosinophilic leukemia (CEL), not otherwise specified (NOS) in 21 (17%) patients. For the remaining 60 (48%) patients, a specific diagnosis was not identified, and 56 patients had HE related findings consistent with idiopathic hypereosinophilic syndrome (HES), while 4 patients who were asymptomatic. With a median follow up of 35.3 months (range, P < .01). Thus, our experience in a single tertiary cancer center shows that the work‐up of HE following WHO recommendations requires a multimodality‐based approach; and a correct diagnosis determines risk stratification and proper patient management. However, the causes of HE remain unknown in approximately half of referred patients, indicating the need for further studies.Keywords
This publication has 36 references indexed in Scilit:
- Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencingPLOS ONE, 2017
- World Health Organization‐defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2017
- Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndromeHaematologica, 2017
- Myeloid neoplasms with eosinophiliaBlood, 2017
- Guideline for the investigation and management of eosinophiliaBritish Journal of Haematology, 2017
- Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specifiedLaboratory Investigation, 2016
- Targeted sequencing identifies patients with preclinical MDS at high risk of disease progressionBlood, 2015
- World Health Organization‐defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2015
- KITD816V and JAK2V617F mutations are seen recurrently in hypereosinophilia of unknown significanceAmerican Journal of Hematology, 2015
- ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor- BHaematologica, 2012